Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

164.42 -1.18 (-0.71%)
Delayed Quote Updated: 12:17 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Second Quarter 2026 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces First Quarter 2026 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2025 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Receives Permanent J-code for Epioxa™
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Third Quarter 2025 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces FDA Approval of Epioxa™
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Second Quarter 2025 Financial Results
From Glaukos Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.